CN114761428B - 抗血凝素抗体及其使用方法 - Google Patents
抗血凝素抗体及其使用方法Info
- Publication number
- CN114761428B CN114761428B CN202080084529.XA CN202080084529A CN114761428B CN 114761428 B CN114761428 B CN 114761428B CN 202080084529 A CN202080084529 A CN 202080084529A CN 114761428 B CN114761428 B CN 114761428B
- Authority
- CN
- China
- Prior art keywords
- influenza
- antibody
- antigen
- binding fragment
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202610591737.8A CN122521584A (zh) | 2019-10-28 | 2020-10-28 | 抗血凝素抗体及其使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926914P | 2019-10-28 | 2019-10-28 | |
| US62/926,914 | 2019-10-28 | ||
| US202063094170P | 2020-10-20 | 2020-10-20 | |
| US63/094,170 | 2020-10-20 | ||
| PCT/US2020/057635 WO2021086899A1 (en) | 2019-10-28 | 2020-10-28 | Anti-hemagglutinin antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610591737.8A Division CN122521584A (zh) | 2019-10-28 | 2020-10-28 | 抗血凝素抗体及其使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114761428A CN114761428A (zh) | 2022-07-15 |
| CN114761428B true CN114761428B (zh) | 2026-05-22 |
Family
ID=73498317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080084529.XA Active CN114761428B (zh) | 2019-10-28 | 2020-10-28 | 抗血凝素抗体及其使用方法 |
| CN202610591737.8A Pending CN122521584A (zh) | 2019-10-28 | 2020-10-28 | 抗血凝素抗体及其使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202610591737.8A Pending CN122521584A (zh) | 2019-10-28 | 2020-10-28 | 抗血凝素抗体及其使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11773156B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4051707A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7611908B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220088446A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114761428B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020374878B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022007923A2 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022001067A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022005281A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292353A (cg-RX-API-DMAC7.html) |
| MY (1) | MY207220A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550963A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021086899A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4508077A4 (en) | 2022-04-14 | 2026-03-25 | Invisishield Tech Ltd | COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108064240A (zh) * | 2014-12-19 | 2018-05-22 | 瑞泽恩制药公司 | 针对流感血凝素的人抗体 |
| WO2019147867A1 (en) * | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| JP6170507B2 (ja) * | 2012-01-31 | 2017-07-26 | 国立大学法人大阪大学 | B型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法 |
| HUE037659T2 (hu) * | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| AU2015214146B2 (en) * | 2014-02-04 | 2020-09-17 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| MX2016012530A (es) * | 2014-03-27 | 2017-01-05 | Genentech Inc | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. |
| WO2016011035A2 (en) * | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| MX389708B (es) * | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| AU2016270147B2 (en) | 2015-06-03 | 2018-08-23 | Xiamen University | Broad-spectrum monoclonal anti-flu B antibody and uses thereof |
| EP3471767A4 (en) * | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| WO2018187706A2 (en) * | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
-
2020
- 2020-10-28 JP JP2022523575A patent/JP7611908B2/ja active Active
- 2020-10-28 WO PCT/US2020/057635 patent/WO2021086899A1/en not_active Ceased
- 2020-10-28 AU AU2020374878A patent/AU2020374878B2/en active Active
- 2020-10-28 CN CN202080084529.XA patent/CN114761428B/zh active Active
- 2020-10-28 IL IL292353A patent/IL292353A/en unknown
- 2020-10-28 EP EP20811191.4A patent/EP4051707A1/en active Pending
- 2020-10-28 BR BR112022007923A patent/BR112022007923A2/pt unknown
- 2020-10-28 MY MYPI2022002059A patent/MY207220A/en unknown
- 2020-10-28 KR KR1020227016672A patent/KR20220088446A/ko active Pending
- 2020-10-28 CN CN202610591737.8A patent/CN122521584A/zh active Pending
- 2020-10-28 US US17/082,375 patent/US11773156B2/en active Active
- 2020-10-28 PH PH1/2022/550963A patent/PH12022550963A1/en unknown
-
2022
- 2022-04-27 CO CONC2022/0005281A patent/CO2022005281A2/es unknown
- 2022-04-27 CL CL2022001067A patent/CL2022001067A1/es unknown
-
2023
- 2023-08-21 US US18/453,207 patent/US20240083983A1/en active Pending
-
2025
- 2025-11-21 AU AU2025271140A patent/AU2025271140A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108064240A (zh) * | 2014-12-19 | 2018-05-22 | 瑞泽恩制药公司 | 针对流感血凝素的人抗体 |
| WO2019147867A1 (en) * | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022007923A2 (pt) | 2022-07-26 |
| CN122521584A (zh) | 2026-08-07 |
| MY207220A (en) | 2025-02-06 |
| JP7611908B2 (ja) | 2025-01-10 |
| AU2025271140A1 (en) | 2026-01-22 |
| WO2021086899A1 (en) | 2021-05-06 |
| CO2022005281A2 (es) | 2022-05-10 |
| IL292353A (en) | 2022-06-01 |
| EP4051707A1 (en) | 2022-09-07 |
| KR20220088446A (ko) | 2022-06-27 |
| CA3153944A1 (en) | 2021-05-06 |
| US11773156B2 (en) | 2023-10-03 |
| JP2022553703A (ja) | 2022-12-26 |
| PH12022550963A1 (en) | 2023-09-25 |
| AU2020374878B2 (en) | 2025-10-16 |
| US20210171612A1 (en) | 2021-06-10 |
| US20240083983A1 (en) | 2024-03-14 |
| CN114761428A (zh) | 2022-07-15 |
| AU2020374878A1 (en) | 2022-04-28 |
| CL2022001067A1 (es) | 2023-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12252530B2 (en) | Human antibodies to Fel d1 and methods of use thereof | |
| CN106414496B (zh) | 针对中东呼吸综合征-冠状病毒刺突蛋白的人抗体 | |
| US20200017576A1 (en) | Human antibodies to influenza hemagglutinin | |
| CN111670195B (zh) | 针对流感血凝素的人抗体 | |
| NZ725965A (en) | Method for biocatalytic whole cell reduction of dehydrocholic acid compounds, and 7-beta-hydroxysteroid dehydrogenase mutants | |
| AU2025271140A1 (en) | Anti-hemagglutinin antibodies and methods of use thereof | |
| HK40111296A (en) | Antibody specific to spike protein of sars-cov-2 and uses thereof | |
| EA046393B1 (ru) | Антитела к гемагглютинину и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |